Pelargonium: The Complete Supplement Guide

Quick Reference Card

Overview

The Basics

Pelargonium sidoides is a flowering plant in the geranium family, native to the Lesotho highlands and the Eastern Cape province of South Africa. For centuries, traditional healers in these regions have used root extracts from this plant to treat respiratory infections, earning it the Zulu name "umckaloabo," which roughly translates to "heavy cough" or "chest-related illness."

In modern use, Pelargonium sidoides root extract has become a widely used over-the-counter remedy in Europe, particularly Germany, where it is sold under brand names and approved for treating acute bronchitis. The extract works differently from conventional cold medicines: rather than simply suppressing symptoms, it appears to target multiple steps in the infection process by fighting bacteria and viruses, stimulating the immune system, and preventing pathogens from attaching to the cells lining your respiratory tract.

The clinical research on Pelargonium focuses almost exclusively on one standardized extract called EPs 7630. Multiple randomized controlled trials and several meta-analyses have examined this extract for acute bronchitis, the common cold, sinusitis, and tonsillopharyngitis (sore throat). The evidence is strongest for acute bronchitis, where multiple studies show that EPs 7630 can reduce symptom severity and shorten illness duration compared to placebo [1][2][3].

The Science

Pelargonium sidoides DC (Geraniaceae) is a perennial herb characterized by dark, heart-shaped leaves and deep tuberous roots. The pharmacologically active constituents are concentrated in the root system and include a complex mixture of oxygenated coumarins (notably umckalin and its sulfate conjugate), polyphenolic compounds (including gallic acid, catechin, and polymeric proanthocyanidins of the prodelphinidin type), and phenolic acids [4][5].

The plant was first introduced to European phytomedicine in the late 19th century, when an Englishman named Charles Henry Stevens traveled to South Africa seeking treatment for tuberculosis and was reportedly cured by a Zulu healer using Pelargonium root preparations. Stevens subsequently marketed the remedy in Britain under the name "Umckaloabo," though its anti-tubercular claims were never validated. The extract lost favor in the early 20th century but experienced a resurgence in Germany in the 1970s, leading to extensive clinical investigation and eventual regulatory approval [6].

The most clinically studied preparation, EPs 7630, is a proprietary ethanol (11% w/w) extract of P. sidoides roots at a drug-to-extract ratio of 1:8-10. This standardization ensures consistent levels of the key bioactive compounds, particularly the prodelphinidin fraction and the characteristic coumarins that serve as chemical fingerprints distinguishing P. sidoides from other Pelargonium species [4][5].

Chemical & Nutritional Identity

The chemical profile of P. sidoides root extract is distinct from other Pelargonium species due to its characteristic coumarin pattern. Umckalin (6,8-dihydroxy-5,7-dimethoxycoumarin) serves as a species-specific marker compound. The prodelphinidin polymers, consisting of gallocatechin and epigallocatechin monomers, are the primary polyphenolic constituents and contribute significantly to the extract's biological activity [4][5].

Other identified compounds include monomeric flavan-3-ols, small quantities of quercetin, and sitosterol-glucoside. The interplay between these compound classes is thought to contribute to the extract's multi-target pharmacological profile, which distinguishes it from single-compound pharmaceuticals [5].

Mechanism of Action

The Basics

Pelargonium sidoides works through a "triple action" approach against respiratory infections, which is why researchers find it interesting compared to conventional treatments that typically target only one mechanism.

First, it fights pathogens directly. The extract has demonstrated antibacterial activity against common respiratory bacteria and antiviral activity against influenza viruses, rhinoviruses, and other respiratory pathogens. Second, it strengthens your immune response by increasing the activity of natural killer cells and improving the ability of white blood cells called phagocytes to engulf and destroy invading organisms. Third, it has an anti-adhesive effect: it helps prevent bacteria from sticking to the mucous membranes lining your throat and airways, which is one of the first steps bacteria take to establish an infection [4][5][7].

This combination of effects means the extract works on multiple fronts simultaneously rather than relying on a single mechanism, which may explain why clinical trials have shown benefits across several types of respiratory infections.

The Science

The pharmacological activity of P. sidoides extract EPs 7630 involves several distinct but complementary mechanisms:

Immunomodulatory Activity: EPs 7630 enhances innate immune function through multiple pathways. In vitro studies demonstrate increased natural killer (NK) cell cytotoxicity, elevated production of tumor necrosis factor alpha (TNF-alpha), inducible nitric oxide synthase (iNOS) activation, and interferon-beta (IFN-beta) release [5]. Conrad et al. (2007) showed that the extract significantly improved peripheral blood phagocyte function by enhancing both oxidative burst capacity and intracellular killing mechanisms [8]. In athletes, P. sidoides extract modulated secretory IgA levels and cytokines (IL-6, IL-15) in nasal mucosa following exhaustive exercise, suggesting potential for maintaining mucosal immune defense during immunosuppressive physiological stress [9].

Antiviral Activity: EPs 7630 exhibits broad-spectrum antiviral effects. Theisen and Muller (2012) demonstrated anti-influenza virus activity both in vitro and in vivo [10]. Michaelis et al. (2011) confirmed activity against a broad panel of respiratory viruses [11]. Roth et al. (2019) elucidated a specific mechanism whereby EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins, including ICAM-1 and LDLR, on human bronchial epithelial cells [12]. Additionally, the extract has been identified as a potent HIV-1 attachment inhibitor, likely through interaction with viral envelope glycoproteins [13].

Antibacterial and Anti-adhesive Activity: The prodelphinidin fraction demonstrates antibacterial effects and, critically, inhibits bacterial adhesion to epithelial surfaces. This anti-adhesive mechanism was specifically demonstrated against Helicobacter pylori in human gastric tissue [14]. Components derived from Pelargonium also stimulate macrophage killing of Mycobacterium species, providing mechanistic support for the historical anti-tubercular claims [15].

Cytoprotective Effects: The polyphenolic constituents exert antioxidant activity that may contribute to protection of respiratory epithelial cells during infection-associated oxidative stress.

Absorption & Bioavailability

The Basics

Pelargonium sidoides extract is taken by mouth, usually as liquid drops, tablets, or syrup. The active compounds are absorbed through the digestive tract, though detailed pharmacokinetic data in humans is limited compared to conventional pharmaceuticals. What researchers do know is that the extract reaches effective concentrations relatively quickly, with many clinical trials reporting onset of symptom relief within the first few days of treatment [1][3].

The liquid drop formulation may offer slightly faster absorption than tablets due to the pre-dissolved state of the active compounds. The ethanol content (11% w/w) in the standard EPs 7630 preparation serves as both a solvent for extraction and a vehicle that may enhance absorption of the lipophilic coumarin compounds.

Whether you take the extract with or without food does not appear to significantly affect its clinical effectiveness based on the available trial data, though no dedicated food-effect pharmacokinetic studies have been published.

The Science

Formal human pharmacokinetic studies for EPs 7630 are limited. The extract represents a complex mixture of compounds rather than a single pharmaceutical entity, making traditional ADME (absorption, distribution, metabolism, excretion) characterization challenging.

The key bioactive fractions include both water-soluble components (proanthocyanidins, gallic acid) and more lipophilic constituents (coumarins such as umckalin). The proanthocyanidin polymers are large molecules with generally low oral bioavailability in their intact form, though monomeric and oligomeric subunits may be absorbed more readily. The coumarins, being smaller and more lipophilic, are expected to cross the intestinal epithelium more efficiently.

The clinical efficacy data from multiple RCTs, demonstrating significant symptom reduction within 3-7 days of treatment, provides indirect evidence that biologically relevant concentrations of active constituents are achieved following oral administration at standard doses [1][2][3].

An animal pharmacokinetic study by Koch and Biber (2007) demonstrated that EPs 7630 does not affect warfarin pharmacokinetics or blood coagulation parameters, providing indirect evidence about the extract's metabolic profile and suggesting it does not significantly inhibit cytochrome P450 enzymes involved in warfarin metabolism [16].

Research & Clinical Evidence

The Basics

Pelargonium sidoides is one of the better-studied herbal supplements for respiratory infections, with multiple randomized controlled trials, several meta-analyses, and a Cochrane systematic review. The evidence is strongest for acute bronchitis, followed by the common cold, and then sinusitis and sore throat.

For acute bronchitis, studies consistently show that taking EPs 7630 for about a week reduces the severity and duration of symptoms, including cough, sputum production, chest pain, and general malaise. In one large trial of 468 adults, those taking the extract recovered nearly two days faster than those taking placebo [1]. A 2023 meta-analysis found that adults with acute bronchitis returned to work an average of 1.73 days sooner when treated with EPs 7630 [17].

For the common cold, a 2019 meta-analysis of five trials (833 patients) showed significant improvements in cold symptom scores, with more than twice as many patients achieving complete remission by day 5 compared to placebo [18].

The evidence for children is also positive. Six clinical trials in children aged 6-10 found that EPs 7630 not only improved symptoms but also reduced the need for pain relievers and allowed children to return to school sooner [19].

The Science

Acute Bronchitis (Adults): The foundational evidence comes from multiple double-blind, placebo-controlled RCTs. Matthys et al. (2003) conducted a pivotal trial of 468 adults with acute bronchitis (present for 48 hours or less), randomized to EPs 7630 or placebo for 7 days. The Bronchitis Severity Score (BSS) decreased by 5.9 +/- 2.9 points in the EPs 7630 group versus 3.2 +/- 4.1 in placebo (95% CI for difference: [-3.359, -2.060], p<0.0001). Onset of treatment effect was recognized within the first four days in 53.6% of the active group versus 36.2% of placebo [1].

Matthys and Funk (2008) reported in a separate 217-patient RCT that BSS decreased by 7.6 +/- 2.2 (EPs 7630) versus 5.3 +/- 3.2 (placebo), p<0.0001. Especially strong antitussive and "anti-fatigue" effects with early onset were noted [3].

The Agbabiaka et al. (2008) systematic review and meta-analysis pooled four placebo-controlled RCTs and confirmed significant reduction in bronchitis symptom scores by day 7 with no serious adverse events [2].

Acute Bronchitis (Children): Kamin et al. (2010) randomized 200 children and adolescents (ages 1-18) to EPs 7630 or placebo for 7 days. BSS improvement was 3.4 +/- 1.8 (EPs 7630) versus 1.2 +/- 1.8 (placebo), p<0.0001. Treatment satisfaction was significantly higher (77.6% vs 25.8%), and onset of effect was faster [20].

Common Cold: Schapowal et al. (2019) conducted a meta-analysis of five RCTs (833 patients, all 10-day treatment periods). Significant differences favored EPs 7630 for total Cold Intensity Score reduction at day 5 (MD = -2.30) and day 10 (MD = -1.16). Complete remission rates were approximately double those of placebo at both time points (day 5: RR = 2.52; day 10: RR = 2.13). Sleep quality improvements and reduced paracetamol use were also observed [18].

Rhinosinusitis: Bachert et al. (2009) demonstrated efficacy in a double-blind, placebo-controlled trial for acute rhinosinusitis [21].

COPD: Matthys et al. (2013) showed effectiveness for moderate to severe chronic obstructive pulmonary disease in a randomized, placebo-controlled trial [22].

Cochrane Review: Timmer et al. (2013) assessed 10 eligible studies (8 included in analyses) covering acute bronchitis (adults and children), sinusitis, and the common cold. The review concluded that P. sidoides may be effective in alleviating symptoms of acute bronchitis in adults and children and acute rhinosinusitis and common cold in adults. However, evidence quality was rated as "low" to "very low" across outcomes, primarily due to the small number of studies per indication and geographic concentration in German, Russian, and Ukrainian clinical settings [23].

Evidence & Effectiveness Matrix

Categories Not Scored: Fat Loss, Muscle Growth, Weight Management, Appetite & Satiety, Food Noise, Sleep Quality, Focus & Mental Clarity, Memory & Cognition, Mood & Wellbeing, Anxiety, Stress Tolerance, Motivation & Drive, Emotional Aliveness, Emotional Regulation, Libido, Sexual Function, Joint Health, Inflammation, Recovery & Healing, Physical Performance, Digestive Comfort, Nausea & GI Tolerance, Skin Health, Hair Health, Heart Health, Blood Pressure, Heart Rate & Palpitations, Hormonal Symptoms, Temperature Regulation, Fluid Retention, Body Image, Bone Health, Longevity & Neuroprotection, Cravings & Impulse Control, Social Connection, Withdrawal Symptoms, Daily Functioning

Benefits & Potential Effects

The Basics

The primary benefits of Pelargonium sidoides are focused squarely on respiratory health. This is not a daily wellness supplement; it is an acute treatment taken when you feel a cold, cough, or bronchitis coming on.

Well-Established Benefits (Strong Evidence):

• Reduced severity of acute bronchitis symptoms, including cough, sputum production, chest pain, and difficulty breathing
• Shorter duration of illness, with patients returning to work approximately 1.5-2 days sooner than with placebo
• Reduced severity and duration of common cold symptoms
• Faster onset of symptom relief compared to placebo (noticeable within the first 3-5 days)
• Reduced need for pain relievers (paracetamol/acetaminophen) during acute respiratory illness, particularly in children

Emerging/Preliminary Benefits:

• Potential benefit in acute rhinosinusitis (sinus infections)
• Possible relief in non-streptococcal sore throat (tonsillopharyngitis)
• Reduced frequency of asthma attacks in children experiencing concurrent respiratory infections
• Symptom alleviation in immunocompromised children with upper respiratory tract infections
• Potential maintenance of mucosal immune function in athletes after exhaustive exercise

The Science

The benefit profile of P. sidoides is tightly aligned with its multi-modal mechanism of action. The immunomodulatory, antiviral, antibacterial, and anti-adhesive properties collectively produce clinical improvements that have been quantified across multiple endpoints:

Bronchitis Symptom Score (BSS): The primary endpoint in most adult bronchitis trials, the BSS measures cough, sputum, chest pain on coughing, dyspnea, and wheezing on a 0-20 scale. Across trials, EPs 7630 consistently reduces BSS by 2-3 points more than placebo over 7 days, a clinically meaningful difference [1][2][3].

Functional Recovery: The 2023 meta-analysis by Matthys et al. is particularly relevant. Among 1,011 patients with acute bronchitis, EPs 7630 reduced the proportion still unable to work from approximately 48% (placebo) to approximately 17% by treatment end, with a weighted mean difference of 1.73 fewer sick days [17].

Pediatric Benefits: In the meta-analysis of six pediatric trials (523 children aged 6-10), EPs 7630 reduced school absence from 74.4% (placebo) to 30.2% at treatment end (RR: 0.43, p<0.001) and reduced cumulative paracetamol consumption, indicating genuine symptom relief rather than simple analgesic masking [19].

Athletic Immune Support: Luna et al. (2011) demonstrated that P. sidoides extract modulated secretory IgA and cytokine profiles in athletes following exhaustive exercise, suggesting a potential role in preventing exercise-induced immunosuppression, an area of emerging research interest [9].

Side Effects & Safety

The Basics

Pelargonium sidoides has a favorable safety profile based on clinical trial data. No serious adverse events have been reported in any of the published randomized controlled trials, and the side effects that do occur are generally mild and resolve after stopping the supplement.

Common Side Effects (Reported in Trials):

• Gastrointestinal upset (stomach discomfort, nausea)
• Allergic reactions (skin rash, itching)
• Diarrhea

Less Common Side Effects:

• Ear and inner ear disturbances
• Psychomotor restlessness (primarily in children)
• Fever
• Exacerbation of existing respiratory symptoms (rare)

Populations Requiring Extra Caution:

• People taking anticoagulant or antiplatelet medications: P. sidoides contains natural coumarins, which have a theoretical potential to affect blood clotting. While an animal study showed no effect on warfarin pharmacokinetics or coagulation parameters [16], clinical data in humans taking concurrent anticoagulants is lacking. Consult a healthcare provider before use.
• People with liver disease: as with many herbal preparations processed by the liver, caution is warranted.
• Pregnant and breastfeeding women: insufficient safety data; use is not recommended without medical guidance.
• Children under 1 year: limited clinical data in this age group.

The Cochrane review noted theoretical safety concerns related to the coumarin content, though these have not been borne out in clinical studies [23].

The Science

Safety data from clinical trials involving over 2,000 participants demonstrates a consistent, favorable tolerability profile for EPs 7630. In the pivotal Matthys et al. (2003) trial of 468 adults, adverse events occurred in 36 patients total (20 in the EPs 7630 group, 16 in placebo), with all events assessed as non-serious [1].

The pediatric safety profile is similarly reassuring. Kamin et al. (2010) reported that tolerability was "similarly good" in both EPs 7630 and placebo groups among 200 children and adolescents [20]. The 2018 review by Kamin et al. examining eight pediatric RCTs confirmed good safety and tolerability across all age groups studied [24].

De Boer et al. (2007) documented allergic reactions to Pelargonium-derived medicines in post-marketing surveillance, noting that while allergic responses can occur, they are uncommon and consistent with general herbal supplement allergy rates [25].

The coumarin-related coagulation concern has been specifically addressed: Koch and Biber (2007) administered EPs 7630 to rats at doses up to 100 times the human equivalent and found no effect on prothrombin time, activated partial thromboplastin time, or warfarin pharmacokinetics [16]. While this does not definitively exclude human risk, it provides meaningful preclinical reassurance.

Knowing the possible side effects is the first step. Catching them early in your own experience is what keeps a supplement routine safe. Doserly lets you log any symptoms as they arise, tagging them with severity, timing relative to your dose, and whether they resolve on their own or persist.

The app's interaction checker cross-references everything in your stack, supplements and medications alike, flagging known interactions before they become a problem. It also monitors your total intake against established upper limits, alerting you if your combined sources of a nutrient are approaching thresholds where risk increases. Think of it as a safety net that works quietly in the background while you focus on the benefits.

Dosing & Usage Protocols

The Basics

Pelargonium sidoides dosing depends on your age, the formulation you are using, and what condition you are treating. Unlike many supplements taken daily for general wellness, Pelargonium is typically used as an acute treatment, taken at the first sign of a respiratory infection and continued for 7-10 days.

Standard Adult Dosing (EPs 7630):

• Liquid drops: 10-30 drops per dose, three times daily (approximately 120-240 mg per day of extract)
• Tablets: 30-90 mg per day (typically 20-30 mg three times daily)
• Duration: 7-10 days

Pediatric Dosing (EPs 7630):

• Ages 1-6: 10 drops three times daily
• Ages 6-12: 20 drops three times daily
• Ages 12-18: 30 drops three times daily
• Duration: 6-7 days

When to Start: Begin treatment as early as possible after symptom onset. The pivotal bronchitis trial required symptoms to be present for 48 hours or less at enrollment. Earlier initiation is associated with better outcomes.

When to Stop: Clinical trials used 7-10 day treatment courses. If symptoms persist beyond 10 days or worsen during treatment, consult a healthcare provider.

The Science

The dose-response relationship for EPs 7630 has been established through multiple clinical trials. The most consistently effective regimen across published RCTs uses the marketed German dosage:

• Liquid preparation: 3 x 30 drops daily (approximately equivalent to 120-240 mg total daily extract)
• Film-coated tablets: 3 x 20-30 mg daily (60-90 mg total daily)
• Treatment duration: 7 days (bronchitis trials) or 10 days (common cold trials)

The pediatric dosing schedule follows age-stratified protocols validated in six clinical trials [19][20]:

The clinical evidence base does not support prophylactic (preventive) use. All positive trials enrolled patients with active symptoms. No study has evaluated whether ongoing daily use prevents future infections [23].

Getting the dose right matters more than most people realize. Too little may be ineffective, too much wastes money or introduces risk, and inconsistency undermines both. Doserly tracks every dose you take, across every form, giving you a clear record of what you're actually consuming versus what you planned.

The app helps you compare RDA recommendations against therapeutic ranges discussed in the research, so you can see exactly where your intake falls. If you switch forms, say from a standard capsule to a liposomal liquid, Doserly adjusts your tracking to account for different bioavailabilities. Pair that with smart reminders that keep your timing consistent, and the precision that makes a real difference in outcomes becomes effortless.

What to Expect (Timeline)

Pelargonium sidoides is an acute treatment, not a daily supplement, so the timeline follows the course of a respiratory illness rather than a gradual accumulation of effects.

Days 1-2:
Most users will not notice dramatic changes in the first 48 hours, though some trials report early symptom stabilization during this period. Continue taking the full dose on schedule. The extract is working to modulate immune responses and limit pathogen adhesion even before symptomatic relief becomes apparent.

Days 3-5:
This is where the clinical evidence shows the clearest separation from placebo. In the common cold meta-analysis, EPs 7630 users were 2.5 times more likely to achieve complete remission by day 5 [18]. In bronchitis trials, over half of treated patients recognized onset of treatment effect within the first four days [1]. Expect noticeable reduction in cough severity, sputum production, and general malaise. Energy levels typically begin to improve, and the "wiped out" feeling of acute illness begins to lift.

Days 5-7:
Symptom resolution accelerates. In adult bronchitis trials, BSS scores improved by approximately 6-8 points on a 20-point scale by day 7 in the treated group, compared to 3-5 points with placebo [1][3]. Most patients are able to return to work and normal activities. Cough may persist at a reduced level.

Days 7-10:
By treatment completion, most clinical trial participants in the EPs 7630 group had substantially resolved or fully remitted symptoms. The common cold meta-analysis showed significant improvements maintained through day 10 [18].

After Treatment:
No withdrawal effects or rebound symptoms have been reported upon discontinuation. If symptoms have not improved by day 10, or if they worsen at any point during treatment, consult a healthcare provider, as this may indicate a bacterial infection requiring different management.

Timelines in the research give you a general idea of when to expect results, but your body has its own schedule. Doserly tracks your progress against those benchmarks, letting you see whether your experience aligns with typical response curves or whether something in your protocol might need adjusting.

By logging biomarkers and subjective outcomes alongside your supplement intake, you build a personal timeline that shows exactly when changes started appearing and how they've progressed. The app's trend analysis highlights inflection points, weeks where things shifted for better or worse, so you have concrete data when deciding whether to continue, adjust your dose, or try a different form.

Interactions & Compatibility

Synergistic

• Vitamin C: Both support immune function during acute respiratory illness through complementary mechanisms. Vitamin C is a well-established antioxidant and immune modulator that may complement Pelargonium's pathogen-targeting effects.
• Zinc: Zinc lozenges have independent evidence for reducing cold duration and severity. The combination addresses mucosal immunity (zinc) and systemic immune modulation plus anti-pathogen activity (Pelargonium) through non-overlapping mechanisms.
• Echinacea: Both are used for acute respiratory infections, though through different mechanisms. Echinacea primarily stimulates immune cell activity while Pelargonium adds anti-adhesive and direct antimicrobial effects. Clinical data on the combination is lacking.
• Elderberry: Elderberry (Sambucus nigra) has evidence for reducing cold and flu duration. Both target viral infections through different pathways.

Caution / Avoid

• Anticoagulant Medications (Warfarin, Heparin): P. sidoides contains natural coumarins. While animal data shows no interaction with warfarin pharmacokinetics [16], clinical human data is absent. Use with caution and medical supervision.
• Antiplatelet Drugs (Aspirin, Clopidogrel): Theoretical concern related to coumarin content. No clinical interaction data available.
• Immunosuppressant Medications: P. sidoides has immunomodulatory properties that could theoretically counteract immunosuppressive therapies. Consult a healthcare provider.
• CYP3A4 Substrates: While no direct evidence exists for P. sidoides CYP inhibition, the complex phytochemical profile warrants caution with drugs heavily dependent on CYP3A4 metabolism.

Supplement-Food Interactions

No clinically significant food interactions have been identified. The liquid preparation contains 11% ethanol, which should be considered by individuals avoiding alcohol for medical, religious, or personal reasons.

How to Take / Administration Guide

Liquid Drops (Most Common Formulation):

• Measure the appropriate number of drops for your age group
• May be taken directly or diluted in a small amount of water
• Take three times daily, spaced approximately evenly throughout the day (morning, midday, evening)
• Continue for the full 7-10 day course even if symptoms improve before completion

Tablets:

• Swallow whole with water
• Take three times daily as directed on the product label
• Do not crush or chew unless the product is specifically designed for this

Syrup (Pediatric):

• Use the measuring device provided with the product
• Dose according to age-specific guidelines
• Can be mixed with a small amount of juice if the child objects to the taste

Timing Considerations:

• No specific meal timing required; can be taken with or without food
• Consistency in timing (same times each day) is more important than relation to meals
• Begin at the earliest sign of respiratory symptoms for best results

Important Notes:

• Pelargonium is for acute (short-term) use during respiratory illness, not for daily preventive supplementation
• The liquid preparation contains ethanol (11% w/w); alcohol-free tablet and syrup formulations are available for those who prefer or require them
• Keep liquid preparations tightly sealed between uses to prevent evaporation of the ethanol solvent

Choosing a Quality Product

Product quality is a significant concern for Pelargonium sidoides supplements, particularly in markets outside of Europe. The vast majority of clinical evidence uses one specific standardized extract (EPs 7630), and products that do not match this standardization may not deliver equivalent results.

What to Look For:

• EPs 7630 standardization: This is the gold standard. Products using this specific extract match the clinical trial formulation. The European brand Kaloba uses EPs 7630.
• Standardization markers: Look for standardization to prodelphinidin content or umckalin levels. Products standardized to "0.3% umckalin" may not match the EPs 7630 prodelphinidin standardization used in clinical trials.
• Extract ratio: The clinical extract uses a 1:8-10 drug-to-extract ratio with 11% ethanol. Products should disclose their extraction method.
• Declared amounts: The label should clearly state the amount of Pelargonium sidoides root extract per dose in milligrams.

Red Flags to Avoid:

• "Homeopathic" labeling: Some widely available products are sold as homeopathic preparations, which by definition contain extremely diluted (potentially negligible) amounts of the active ingredient. These do not match the concentrated root extract used in clinical trials.
• No standardization information: Products that list only "Pelargonium sidoides" without specifying extract amount, standardization, or extraction method provide no assurance of active compound levels.
• Proprietary blends: Products combining Pelargonium with multiple other herbs in undisclosed amounts make it impossible to determine if you are getting an effective dose.
• No contact information for the manufacturer: Reputable companies provide customer service access and can supply Certificates of Analysis upon request.

Third-Party Testing:

• USP Verified and NSF International certifications are not commonly available for Pelargonium products given its niche status in the US market
• ConsumerLab has periodically tested Pelargonium products and may provide comparison data
• Requesting a Certificate of Analysis (CoA) from the manufacturer is advisable, particularly for brands without established track records

Storage & Handling

• Store at room temperature (15-25 C / 59-77 F)
• Protect from direct sunlight and excessive heat
• Keep liquid preparations tightly sealed to prevent ethanol evaporation, which could alter the concentration of active compounds
• Keep out of reach of children (liquid preparations contain ethanol)
• Check expiration dates; herbal extracts can lose potency over time
• No refrigeration required for standard formulations
• If traveling, keep liquid bottles upright and secured to prevent leakage; tablet formulations may be more convenient for travel

Lifestyle & Supporting Factors

Pelargonium sidoides is used as an acute treatment during respiratory illness rather than as a daily wellness supplement, so the lifestyle factors most relevant to its effectiveness are those that support immune function and recovery from infection.

Hydration: Adequate fluid intake during respiratory illness supports mucous membrane function, helps thin secretions, and aids recovery. The liquid formulation of Pelargonium is typically diluted in water, which contributes modestly to hydration.

Rest: Sleep and physical rest are critical during acute respiratory illness. Clinical trials noted that EPs 7630 reduced time confined to bed, but this reflects symptom improvement, not a recommendation to resume strenuous activity prematurely.

Nutrition: Maintaining adequate intake of immune-supportive nutrients (vitamin C, zinc, vitamin D) during illness may complement Pelargonium's effects. Warm liquids, soups, and easily digestible foods support recovery.

Avoiding Irritants: Tobacco smoke, excessive alcohol, and dry air can worsen respiratory symptoms and potentially interfere with the extract's mucosal protective effects.

Exercise: During acute illness, vigorous exercise is generally not recommended regardless of supplement use. As symptoms resolve (typically days 5-7 with Pelargonium treatment), light activity can be gradually resumed.

Stress Management: Psychological stress suppresses immune function. The short treatment course (7-10 days) means that stress management during acute illness is the primary consideration.

Regulatory Status & Standards

United States (FDA):
Pelargonium sidoides root extract is marketed as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved as a drug for any indication. No GRAS (Generally Recognized as Safe) designation has been issued. Products are available without prescription.

Germany (BfArM):
EPs 7630 was approved in 2005 as a traditional herbal medicinal product for the treatment of acute bronchitis. It is registered and regulated as an herbal medicine (phytopharmacon) and is available as an over-the-counter product. Germany is the primary market, and the regulatory approval is based on traditional use evidence combined with clinical trial data.

European Union (EFSA/EMA):
The European Medicines Agency (EMA) has assessed Pelargonium sidoides root extract. It is available as a traditional herbal medicinal product in several EU member states. EFSA has not established specific health claims for the substance.

Canada (Health Canada):
Available as a Natural Health Product. NPN-registered Pelargonium products are available.

Australia (TGA):
Available as a complementary medicine. Listed on the Australian Register of Therapeutic Goods.

Athlete & Sports Regulatory Status:

• WADA: Pelargonium sidoides is not on the World Anti-Doping Agency Prohibited List. It is not classified as a prohibited substance in-competition or out-of-competition.
• National Anti-Doping Agencies: No specific alerts or guidance have been issued by USADA, UKAD, Sport Integrity Canada, or Sport Integrity Australia regarding Pelargonium sidoides.
• Professional Sports Leagues: No league-specific restrictions (NFL, NBA, MLB, NHL, NCAA) are known to apply to Pelargonium sidoides.
• Athlete Certification Programs: Due to its niche market position, few Pelargonium products carry Informed Sport, NSF Certified for Sport, or Cologne List certification. Athletes should verify specific products before use.
• GlobalDRO: Athletes can check the status of specific products at GlobalDRO.com.

Regulatory status and prohibited substance classifications change frequently. Athletes should always verify the current status of any supplement with their sport's governing body, their national anti-doping agency, and a qualified sports medicine professional before use. Third-party certification (Informed Sport, NSF Certified for Sport) reduces but does not eliminate the risk of contamination with prohibited substances.

Frequently Asked Questions

Is Pelargonium sidoides the same as regular geranium?
No. While Pelargonium sidoides belongs to the Geraniaceae (geranium) family, it is a distinct species native to South Africa. The ornamental geraniums commonly found in gardens (Pelargonium x hortorum) are different species and do not have the same medicinal properties. Only P. sidoides root extract has been studied for respiratory health.

Can I take Pelargonium to prevent colds?
No clinical evidence supports preventive (prophylactic) use. All positive clinical trials enrolled patients who already had active symptoms. There are no studies examining whether daily Pelargonium use prevents future infections. It is designed as an acute treatment, not a daily supplement.

Is Umcka the same as EPs 7630?
Not necessarily. "Umcka" is a brand name used by Nature's Way, but some of their products are labeled as homeopathic preparations, which may contain extremely diluted amounts of the active ingredient. EPs 7630 is a specific standardized root extract used in clinical trials. These are not equivalent formulations. Check the label carefully for extract amount and standardization information.

How quickly does Pelargonium work?
Based on clinical trial data, most users begin noticing symptom improvement within 3-5 days. In the pivotal bronchitis trial, over half of treated patients recognized onset of effect within the first four days. Complete or substantial remission is typically achieved within 7-10 days of treatment.

Can children take Pelargonium?
Yes, with appropriate age-based dosing. Clinical trials have enrolled children as young as 1 year old and have consistently reported good safety and tolerability. Pediatric dosing uses reduced amounts (10-20 drops three times daily depending on age). Always consult a pediatrician before giving herbal supplements to children.

Does Pelargonium interact with blood thinners?
P. sidoides contains natural coumarins, which theoretically could affect blood clotting. However, an animal study using doses up to 100 times the human equivalent found no effect on coagulation parameters or warfarin pharmacokinetics. Clinical human data on this interaction is not available. If you take blood thinners, consult your healthcare provider before using Pelargonium.

Is the alcohol in liquid Pelargonium preparations a concern?
The standard EPs 7630 liquid preparation contains 11% ethanol. At a typical adult dose of 30 drops three times daily, the total daily alcohol intake is very small. However, alcohol-free tablet and syrup formulations are available for those who prefer or need to avoid alcohol, including for pediatric use.

Can I take Pelargonium with antibiotics?
There are no known clinical interactions between Pelargonium and antibiotics. However, if your healthcare provider has prescribed antibiotics, it is important to follow their guidance. Pelargonium is positioned as an alternative to unnecessary antibiotic use for viral respiratory infections, not as a replacement for antibiotics when they are genuinely needed.

Is Pelargonium effective against COVID-19 or influenza?
In vitro studies demonstrate antiviral activity against influenza viruses and a broad panel of respiratory viruses. However, no clinical trials have specifically tested Pelargonium against COVID-19 or confirmed influenza. The clinical evidence is for the common cold and acute bronchitis. Do not use Pelargonium as a substitute for recommended antiviral treatments or vaccination.

Why is Pelargonium more popular in Europe than in the US?
Pelargonium sidoides extract (as Kaloba/Umckaloabo) has been an established over-the-counter remedy in Germany since 2005 and has regulatory approval as a traditional herbal medicinal product. The US market has been slower to adopt it, partly due to regulatory differences (dietary supplement vs. approved medicine), partly due to product quality inconsistencies (some US products use homeopathic labeling rather than standardized extracts), and partly due to lower consumer awareness.

Myth vs. Fact

Myth: Pelargonium is just another form of echinacea.
Fact: Pelargonium sidoides and echinacea are completely different plants with different active compounds and different mechanisms of action. While both are used for respiratory infections, echinacea primarily stimulates immune cell proliferation, whereas P. sidoides acts through a combination of direct antimicrobial activity, immune modulation, and anti-adhesive effects that prevent pathogens from binding to respiratory tract cells [4][5].

Myth: "Homeopathic" Pelargonium products are equivalent to standardized extracts.
Fact: Homeopathic preparations by definition use extreme dilutions and may contain negligible amounts of actual Pelargonium extract. The clinical evidence supporting Pelargonium for respiratory infections uses concentrated standardized root extracts (EPs 7630), not homeopathic dilutions. Products labeled as "homeopathic" should not be assumed to deliver the same benefits demonstrated in clinical trials.

Myth: Pelargonium can replace antibiotics for bacterial infections.
Fact: While Pelargonium has shown antibacterial properties in laboratory studies, it is not a substitute for antibiotics when bacterial infection is confirmed or strongly suspected. Clinical trials position it as an alternative for the majority of respiratory infections that are viral in nature and where antibiotics are ineffective and inappropriately prescribed. If a healthcare provider diagnoses a bacterial infection and prescribes antibiotics, follow their guidance [1][23].

Myth: Natural coumarins in Pelargonium make it dangerous for everyone.
Fact: While P. sidoides does contain oxygenated coumarins (including umckalin), these are structurally different from the synthetic coumarins used in anticoagulant drugs. An animal study administering doses up to 100 times the human equivalent found no effect on blood clotting or warfarin metabolism [16]. In clinical trials involving over 2,000 participants, no coagulation-related adverse events were reported. The concern is theoretical and primarily relevant for individuals already taking anticoagulant medications, who should consult their healthcare provider.

Myth: All Pelargonium supplements are equally effective.
Fact: Nearly all clinical evidence uses one specific extract: EPs 7630. Different extraction methods, different drug-to-extract ratios, and different standardization markers can yield products with substantially different chemical profiles. A product labeled as containing "Pelargonium sidoides" is not automatically equivalent to EPs 7630. Look for products that specify their extract type, standardization, and dose.

Myth: You should take Pelargonium daily to prevent getting sick.
Fact: No clinical trial has tested daily preventive use. All positive evidence comes from studies of acute treatment (beginning after symptom onset). There is no basis for recommending daily prophylactic use, and the long-term safety of continuous administration has not been established [23].

Myth: Pelargonium is just a placebo, as the Cochrane review rated the evidence as "low quality."
Fact: The Cochrane review's "low" and "very low" quality ratings reflect the grading system's assessment of the overall evidence base (few studies per indication, limited geographic diversity), not a conclusion that the treatment does not work. The individual trials are generally well-designed with high methodological quality scores, and effect sizes are consistent and statistically significant across multiple meta-analyses [2][17][18][23].

Sources & References

Clinical Trials & RCTs

1. Matthys H, Eisebitt R, Seith B, Heger M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine. 2003;10 Suppl 4:7-17.
2. Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. Phytomedicine. 2008;15(5):378-385.
3. Matthys H, Funk P. EPs 7630 improves acute bronchitic symptoms and shortens time to remission. Results of a randomised, double-blind, placebo-controlled, multicentre trial. Planta Med. 2008;74(6):686-692.

Systematic Reviews & Meta-Analyses

1. Matthys H, Funk P, Zimmermann A, Lehmacher W. Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysis. Multidiscip Respir Med. 2023;18(1):914.
2. Schapowal A, et al. Treatment of signs and symptoms of the common cold using EPs 7630 - results of a meta-analysis. Heliyon. 2019;5(11):e02904.
3. Meta-analysis of EPs 7630 in children with acute respiratory tract infections. BMC Pediatr. 2019;19:119.
4. Timmer A, Gunther J, Motschall E, Rucker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev. 2013;(10):CD006323.
5. Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety in children. Pediatr Pulmonol. 2018.

Mechanistic & In Vitro Studies

1. Kolodziej H. Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo. Phytomedicine. 2007;14 Suppl 6:9-17.
2. MSKCC About Herbs database: Pelargonium sidoides. Mechanism of Action section. Last updated July 24, 2023.
3. Kayser O, Kolodziej H. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med. 1997;63(6):508-510.
4. Conrad A, Hansmann C, Engels I, Daschner FD, Frank U. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. Phytomedicine. 2007;14 Suppl 6:46-51.
5. Luna LA Jr., Bachi AL, Novaes EBRR, et al. Immune responses induced by Pelargonium sidoides extract in serum and nasal mucosa of athletes after exhaustive exercise. Phytomedicine. 2011;18(4):303-308.
6. Theisen LL, Muller CP. EPs 7630 (Umckaloabo), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo. Antiviral Res. 2012;94(2):147-156.
7. Michaelis M, Doerr HW, Cinatl J Jr. Investigation of the influence of EPs 7630 on replication of a broad panel of respiratory viruses. Phytomedicine. 2011;18(5):384-386.
8. Roth M, Fang L, Stolz D, et al. Pelargonium sidoides radix extract EPs 7630 reduces rhinovirus infection through modulation of viral binding proteins on human bronchial epithelial cells. PLoS One. 2019;14(2):e0210702.
9. Helfer M, Koppensteiner H, Schneider M, et al. The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor. PLoS One. 2014;9(1):e87487.
10. Wittschier N, Faller G, Hensel A. An extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomach. Phytomedicine. 2007;14(4):285-288.
11. Kim CE, Griffiths WJ, Taylor PW. Components derived from Pelargonium stimulate macrophage killing of Mycobacterium species. J Appl Microbiol. 2009;106(4):1184-1193.

Safety & Pharmacology

1. Koch E, Biber A. Treatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin. Phytomedicine. 2007;14 Suppl 6:40-45.
2. Kamin W, Maydannik V, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis. Int J Clin Pharmacol Ther. 2010;48(3):184-191.
3. de Boer HJ, Hagemann U, Bate J, Meyboom RH. Allergic reactions to medicines derived from Pelargonium species. Drug Saf. 2007;30(8):677-680.

Government & Institutional Sources

1. Bladt S, Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo. Phytomedicine. 2007;14(Suppl 6):2-4.
2. Bachert C, Schapowal A, Funk P, Kieser M. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial. Rhinology. 2009;47(1):51-58.
3. Matthys H, Pliskevich DA, Bondarchuk OM, et al. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD. Respir Med. 2013;107(5):691-701.

Related Supplement Guides

Same Category (Herbal / Botanical)

• Echinacea
• Elderberry
• Andrographis
• Astragalus

Common Stacks / Pairings

• Vitamin C
• Zinc
• Vitamin D3

Related Health Goal (Immune Support)

• Probiotics
• Beta-Glucans
• N-Acetylcysteine (NAC)
• Quercetin